Objective Antibiotics are the drugs most frequently prescribed for children, and most of them lack patent protection. The aim of this study was to evaluate off-label antibiotic use in three European countries. Methods Data relating to all patients admitted to the neonatal intensive care units (NICUs) and paediatric wards of the participating centres were collected by the same investigator over a 2-week survey period between February and May 2009. The data included age, date of birth, weight, relevant medical history and diagnosis, together with details of all of the antibiotics prescribed (compound, route of administration, dose, and indication for use). Results The study involved 616 children (110 admitted to NICUs: 62 in the UK, 38 in Italy and 10 in Greece; 506 admitted to general paediatric wards: 265 in the UK, 94 in Italy and 147 in Greece). A total of 1244 antibiotic prescriptions were issued (290 in NICUs and 954 in paediatric wards). The results showed that off-label antibiotic use is very common among European paediatric patients, with generally only slight, but sometimes significant differences between countries. However, this use relates almost exclusively to doses and indications, and rarely to age. The only antibiotics found to be used off-label in an age-related manner in paediatric clinical practice are meropenem for neonates and quinolones or linezolid for older children, which represent priorities for future studies. Conclusion European-wide educational programmes are urgently needed to meet the objectives of improving paediatricians' working knowledge of the recommendations surrounding licensed antibiotics-use in children, and of reducing uncontrolled patterns of prescribing.
Introduction
A number of hospital-and office-based studies have shown that many of the drugs prescribed to children are used outside their registered doses, age groups, indications and routes of administration [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . This off-label use is related to the practical and ethical difficulties in carrying out clinical trials involving very young subjects. The extensive research required by current standards of drug evaluation in order to register a specific product for paediatric use is often not supported by the profit-driven drug industry because children represent only a small part of the drug market [13] . Furthermore, the limited paediatric drug research that is carried out is often based on small-scale studies that lack the statistical power necessary to draw any firm conclusions concerning the real efficacy of the drugs or their long-term toxic effects [14] . Ethical conflicts are heightened in cases where the toxicity of medicines may be different in children and adults, compounded by issues around informed consent and assent [15] .
Off-label drug use can cause significant damage in the developing fetus or child, with one of the best examples being the grey baby syndrome due to chlorampenicol [16, 17] , and it also gives rise to many minor but not marginal adverse events requiring hospitalisation or additional therapies [18] [19] [20] [21] [22] . A number of health authorities have recognised the need to conduct specific studies in children in order to reduce the problem of off-label use. The American Food and Drug Administration (FDA) has prepared the Best Pharmaceutical for Children Act and the Pediatric Research Equity Act, both of which are intended to incentivise drug research in children [23, 24] : the first allows companies to qualify for an additional 6 month of exclusive marketing of a specific molecule provided that they carry out specific paediatric trials [23] , and the second, which became law in 2003, states that the FDA can require paediatric studies of a drug for which a new drug application is submitted if it finds that the product is likely to be used in a substantial number of paediatric patients or would provide a significant benefit over existing treatments [24] . The European Medicines Agency (EMA) has laid down specific rules for marketing authorisations of new medicinal products and for paediatric-use marketing authorisations of off-patent products [25] . It has also agreed upon a strategy for establishing the European network of paediatric research and providing information on paediatric clinical trials. Moreover, in order to encourage studies of drugs that lack patent protection because they have been marketed for many years, it has decided to prepare a list of drugs for which studies in children are urgently needed and can be financed by the European Union [26] .
The drugs most frequently prescribed for children are antibiotics [27, 28] , most of which lack patent protection. The aim of the study reported here was to evaluate off-label antibiotic use in three European countries.
Methods
Antibiotic prescriptions were evaluated for all inpatients in the neonatal intensive care units (NICUs) and the paediatric medical and surgical wards of two hospitals in the UK (St George's Hospital and Evelina Children's Hospital, both in London), one hospital in Italy (Department of Maternal and Pediatric Sciences of the University of Milan), and one hospital in Greece (Aglaia Kyriakou Children's Hospital, University of Athens). All data obtained on patients presenting at the four sites were collected by the same investigator (AP) during a 2-week survey of each hospital between February and May 2009. Data included age, date of birth, weight, relevant medical history and diagnosis, together with details of all of the antibiotics prescribed (compound, route of administration, dose and indication for use). The protocol was approved by the Institutional Review Board of all centres, and written informed consent was obtained from a parent or legal guardian, with children older than 8 years of age being asked to give personally their assent.
Off-label antibiotic use was determined on the basis of the information relating to product registration given in the British National Formulary 2009, the Italian Informatore Farmaceutico and the Greek National Formulary 2006 and on the package insert information as well as what could be derived from the medical information departments of the pharmaceutical companies concerned. Off-label use was defined as the administration of an antibiotic in situations not covered by the product licence or the summary of product characteristics, or at a different dose or frequency, or to different age groups, or by means of an alternative route. The age groups considered were those defined by EMA: neonates (0-27 days), infants (28 days to 23 months), children (2-11 years) and adolescents (12-17 years). The prescriptions were then divided into three groups depending on whether the off-label use was related to the patient's age, the drug dose or the indication. A difference of 10% between the physician's prescription and the reference dose was allowed before the administration was considered to be off-label.
Results were compared using SAS software ver. 9.1 (SAS Institute, Cary, NC). In the tables, only antibiotics prescribed at an unregistered dose or for an off-label indication in more than 5% of the prescriptions in at least one of the centres are shown. Categorical variables are reported as numbers and percentages and analysed by means of contingency tables and the chi-squared or Fisher's test. Continuous variables are given as mean values ± standard deviation (SD) and analysed using a t test or Wilcoxon's test (for non-normally distributed data). P values ≤0.05 were considered to be statistically significant.
Results

Study population
The study involved a total of 616 children (110 admitted to NICUs: 62 in the UK, 38 in Italy, 10 in Greece; 506 admitted to paediatric wards: 265 in the UK, 94 in Italy, 147 in Greece). A total of 1244 antibiotic prescriptions were issued for these patients (290 in NICUs and 954 in paediatric wards). Table 1 shows the demographic characteristics of the study patients. For NICU patients, there were no significant between-country differences in gender or age or in the presence of underlying chronic conditions, number of antibiotic prescriptions, number of antibiotics used, or clinical indications for the antibiotic prescriptions. With respect to admittance to paediatric wards, significantly more children in the neonatal age group were admitted in the UK than in Italy or Greece, and significantly fewer children aged 2-11 years were admitted in the UK than in Greece, while both UK and Italy hospitalised significantly more paediatric patients with underlying chronic diseases than Greece. However, there were no significant betweencountry differences in gender, number of antibiotic prescriptions, number of antibiotics used, or clinical indications for the antibiotic prescriptions on paediatric wards.
Antibiotic prescribing in neonatal units
There were 12 episodes out of 290 prescriptions in which antibiotics were used outside the registered age range (4.1%). Although there was a small number of neonates in the Greek NICU during the study period, there were significantly fewer "outside age range" prescriptions in the UK (4/172, 4.3%) and Italy (2/91, 2.2%) than in Greece (6/ 27, 22.2%; p<0.05 vs UK and Italy). Meropenem was the most frequent of such prescriptions in all centres (10/12 episodes, 83.3%) and was prescribed because of proven or suspected sepsis in all cases. The Greek NICU also used imipenem (one case for lower respiratory tract infection) and ciprofloxacin (one case for urinary tract infection) outside the age range. Moreover, the median gestational and chronological ages of the neonates for whom antibiotics were used outside the registered age range were significantly lower in Italy (median gestational age at birth 26 weeks, median age at prescription 24 days) than in the UK [median gestational age at birth 31.7 weeks (p<0.05 vs. Italy); median age 39.5 days (p<0.05 vs. Italy)] or Greece [median gestational age 33.7 weeks (p<0.05 vs. Italy); median age 64 days (p<0.05 vs. Italy)]. The off-label use of antibiotics in the UK and Italian NICUs was related to patients with an underlying chronic disease in all cases, whereas in Greece, this was true of only half of the cases. Table 2 shows the antibiotics used at an unregistered dose in more than 5% of the prescriptions in at least one of the centres where patients were admitted to NICUs. The number of such prescriptions was high in all three countries, but it was significantly higher in Italy than in the UK. In all of the NICUs, the antibiotics most frequently prescribed at doses other than the recommended dose were the aminoglycosides (particularly amikacin and gentamicin). Off-label doses of gentamicin and also amoxicillinclavulanate were prescribed significantly more often in the Italian NICU than in the UK units. In most cases, the differences consisted of the administration of a lower than advised total daily dose or different fractioning. Higher than recommended doses were significantly more common in the Greek than in the UK NICUs. The most common clinical indication related to the use of off-label doses was proven or suspected sepsis in all three countries, although significantly more off-label doses for medical prophylaxis were prescribed in Italy and Greece than in the UK. Table 3 shows the antibiotics used for an off-label indication in more than 5% of the prescriptions in at least one of the centres in the patients admitted to the NICUs. The prevalence of this use was similar in the UK and Greece, but higher in Italy. There were between-country differences in both the molecules and the individual Table 4 shows the antibiotics used at an unregistered dose in more than 5% of the prescriptions in at least one of the centres for patients admitted to paediatric wards. The proportion of prescriptions was quite similar in all of the centres, and the number of antibiotics involved was equally high across countries. In contrast, there were significant between-country differences in antibiotic choice, the most commonly prescribed antibiotic being amoxicillin-clavulanate in Italy, cefuroxime in Greece and gentamicin in the UK. The off-label doses were mainly higher than advised in Italy and Greece and lower than recommended in the UK. The main indications for off-label dosage were sepsis, lower respiratory tract infection and surgical prophylaxis in all three countries, with no difference in prevalence. Doses other than those recommended were used for children aged 28 days-23 months significantly more often in Italy than in the UK or Greece, with the median age of children receiving off-label doses being significantly lower in Italy than in the other two countries. Off-label doses were prescribed for children with underlying chronic disease Table 5 shows the antibiotics used for off-label indications in more than 5% of the prescriptions in at least one of the centres. The frequency of this use was significantly higher in the UK and Italy than in Greece. Amoxicillinclavulanate was prescribed significantly more often in Italy than in Greece, and ampicillin-sulbactam was prescribed significantly more often in Italy than in UK and Greece. The prevalence of use for off-label surgical treatment was significantly higher in the UK and Italy than in Greece. There were no significant between-country differences in the age distribution of the patients or the presence of an underlying chronic disease.
Discussion
Over the last few years, several studies carried out in different settings have clearly demonstrated that the offlabel use of drugs is frequent in the field paediatrics, especially in neonates [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . However, most of these studies have considered all drugs prescribed to children and provided few details on prescription practice. To the best of our knowledge, this is the first study evaluating off-label antibiotic use in paediatric patients that takes into account all of the variables involved in a drug prescription: the age of the patient, the total daily drug dose and its fractioning and the indication for treatment.
Our findings suggest that paediatric off-label antibiotic use is very common in Europe, with only marginal, but sometimes significant between-country differences. However, this off-label use almost exclusively relates to doses and indications rather than age, as the only antibiotics not registered for specific age groups that neonatologists and paediatricians sometimes deem imperative in very serious clinical situations were meropenem for neonates and quinolones or linezolid for older children.
Sepsis in an NICU is a life-threatening disease that requires prompt and effective antibiotic treatment [29] . Published recommendations suggest that the empirical therapy for newborns should be based on a combination of ampicillin and an aminoglycoside, although the latter can cause severe adverse events and has to be administered cautiously in the first months of life [29] . However, most of the pathogens that cause neonatal bacterial sepsis have become highly resistant to the first-choice combination, especially in the case of a late-onset and probable nosocomial origin [30] . This means that alternative antibiotic therapies are needed, particularly for neonates who remain in NICUs for several days, justifying the use of meropenem in some cases. Meropenem has a broad antibacterial spectrum, a very good safety profile and good pharmacokinetic and pharmacodynamic characteristics [31] . However, although it has been widely successfully used to treat severe infections, including bacterial sepsis and meningitis in children and infants aged ≥3 months [32] , it has not yet been registered for neonates and infants aged Table 3 Antibiotics used for an off-label indication in more than 5% of the prescriptions in at least one of the centres for patients admitted to NICUs Antibiotics used for an off-label indication in more than 5% of the prescriptions UK (no. <3 months. Our data show that comprehensive clinical research into its use for severe infections in this age group is a clinical priority for neonatologists. Quinolones and linezolid are not licensed for use during the first 18 years of life, but studies of quinolones have clearly demonstrated that ciprofloxacin and levofloxacin (the molecules used in the centres involved in this study) can be administered to paediatric patients with good results and without any significant adverse events [33, 34] . Nevertheless, the use of quinolones should be limited to diseases caused by pathogens resistant to all of the other licensed drugs because they may rapidly select for antimicrobial resistance in the case of widespread and uncontrolled administration. The situation of linezolid is similar, as it is a relatively new drug for which paediatric experience is limited to complicated infections in patients with underlying chronic disease [35] [36] [37] . We found that quinolones and linezolid were mainly used in children with cystic fibrosis or oncohaematological diseases in which complicated infections due to bacterial resistance to commonly used antibiotics are very frequent.
The high prevalence of antibiotic prescriptions for offlabel indications or at unregistered doses in our NICUs and paediatric wards is in line with previously published data concerning the paediatric use of antibiotics [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . It may be that paediatricians have a poor understanding of the properties and characteristics of antibiotics or how they should be prescribed to treat bacterial diseases at different paediatric ages, but our findings raise some interesting afterthoughts.
First of all, certain antibiotics, especially aminoglycosides, were prescribed at below than recommended doses, mainly in the UK and Italian NICUs, which may reflect neonatologists' fear of known adverse effects [2] and a preference to reduce the risk by limiting dosage rather than respecting published recommendations. The higher than recommended dosage of aminoglycosides observed for the NICU in Greece is difficult to explain, but it highlights the need for a comprehensive review of the dosing of potentially toxic antibiotics in such setting.
Secondly, the main off-label indications for which antibiotics were used in NICUs were proven or suspected sepsis in the UK and medical prophylaxis in Italy and Greece. The rational approach to antibiotics in neonates involves using narrow-spectrum drugs whenever possible, treating infection and not colonisation, and limiting the duration of therapy [30] , which makes it difficult to explain their use for off-label indications. It is possible that many of the antibiotics approved for use in neonates have been licensed for so long that the emergence of bacterial resistance is being observed or suspected, underpinning the tendency to move to off-license alternatives. Thirdly, for the paediatric inpatient populations, the number of prescriptions made at unregistered doses could be due to clinicians translating the findings of wellconducted post-marketing studies into their clinical practice. Aminoglycosides serve as a good example of this: having been licensed with the recommendation to divide the total daily dose into two or three administrations depending on the patients' age and renal function, subsequent clinical trials have shown equivalent or superior clinical outcomes from once-daily dosing of the total daily dose, with a reduced lower risk of toxicity [38, 39] . Similarly, amoxicillin, licensed in children at a recommended dose of 40-50 mg/kg/day, proved to be effective against Streptococcus pneumoniae strains with relative resistance to penicillin when used at a higher dose (80-90 mg/kg/day) without concomitant increase in the incidence of adverse events [40, 41] .
Evidence of the clinical effectiveness of other antimicrobials when used for off-label indications may also be influencing practice: for example, the use of macrolides for bronchitis or acute infectious wheezing was not considered appropriate until the role of atypical bacteria was demonstrated in these diseases [42] [43] [44] . It may be, therefore, that some of the off-label prescribing described in this study constituted active rational decision-making by clinicians based on the emerging evidence. However, how much offlabel prescribing is merely "personal practice" error or experimentation without an appropriate clinical trial setting cannot be evaluated from this study.
In conclusion, although only four centres have been evaluated in our study, which limits any speculation on the possible causes of differences between countries as well as not truly representative of the entire European Union, our data confirm that the off-label use of antibiotics in newborns, infants and children is widespread and that the bulk of this cannot be justified on the grounds of optimising clinical care. As suggested by the FDA and EMA [23] [24] [25] [26] , studies on antibiotics not licensed for specific paediatric age groups are urgently needed in order to evaluate how these antibiotics should be administered with the aim of optimising clinical results while minimising the risk of adverse events. In the case of already licensed antibiotics, studies performed after their licensing should be carefully reviewed and the recommendations modified when new knowledge is acquired. Finally, national and European-wide educational programmes should meet the dual objectives of improving paediatricians' working knowledge of the recommendations surrounding licensed antibiotics-use in children and of reducing uncontrolled patterns of prescribing that may increase the risk of antimicrobial resistance. 
